Skip to main navigation
Skip to main content
Skip to Footer

Navigate Novartis

Global
- Novartis site directory

Our Company
Our Focus
Our Science
Careers

All News

Advanced Search Basic Search

From Date:

To Date:

Show:

All

Featured News

Media Releases

In the News

Stories

Statements

Filter By

Language:

En

Fr

De

2019

December

Media Release / Dec 05, 2019

Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day

September

Media Release / Sep 29, 2019

Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients

July

Media Release / Jul 31, 2019

Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials

June

Media Release / Jun 01, 2019

Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial

May

Media Release / May 23, 2019

Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event

Media Release / May 16, 2019

Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

2018

December

Media Release / Dec 08, 2018

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

November

Media Release / Nov 16, 2018

Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer

Media Release / Nov 02, 2018

Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology

July

Media Release / Jul 18, 2018

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Search Results Navigation

Current page 1 of 5
Page 2 of 5
Page 3 of 5
Page 4 of 5
Page 5 of 5
Next page
Last page

Related Links

Stay Up-to-Date
Novartis SEC Filings
Novartis Social Business Resources
What should I know before joining a clinical trial?

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

You are here

Home ›
Media

Novartis Global

Navigate Novartis
Contact Us
About Novartis
Our Portfolio
- Global Product Portfolio
- Global Clinical Pipeline
Careers
- Career Search

Subscribe to Novartis

twitter
linkedin
youtube
facebook
instagram

Novartis Site Directory

© 2019 Novartis AG

Terms of Use
Privacy Policy
Contact Us
Site Map

This site is intended for a global audience.